期刊文献+

tPSA灰区f/tPSA与PSAD对前列腺癌与前列腺增生伴前列腺炎的诊断价值 被引量:10

Diagnostic effectiveness of f/tPSA and PSAD in PSA gray zone for diagnosis of prostate cancer and prostatic hyperplasia accompanied with prostatitis
原文传递
导出
摘要 目的探讨在总前列腺特异性抗原(tPSA)灰区(tPSA为4~10 ng/ml)前列腺特异性抗原(PSA)、游离前列腺特异性抗原/总前列腺特异性抗原(f/tPSA)、前列腺特异性抗原密度(PSAD)对前列腺癌(PCa)与前列腺增生伴前列腺炎的诊断价值。方法回顾性分析2016年9月至2018年9月tPSA位于4~10 ng/ml的前列腺疾病患者96例临床资料,经病理证实PCa 26例,BPH伴前列腺炎70例,统计tPSA、游离PSA(fPSA),PSA比值(f/tPSA)、PSA密度(PSAD),分别计算f/tPSA与PSAD对PCa诊断的敏感性、特异性。结果 PCa组tPSA水平与BPH伴前列腺炎组比较,差异未见统计学意义(P>0.05)。PCa组f/tPSA水平与BPH伴前列腺炎组比较,差异有统计学意义(P<0.05),PCa组f/tPSA低于BPH伴前列腺炎组。PCa组PSAD水平与BPH伴前列腺炎组比较,差异有统计学意义(P<0.05),PCa组PSAD高于BPH伴前列腺炎组。当f/tPSA临界值取0.16时,其对PCa诊断敏感性为70.11%,特异性为57.10%;当PSAD临界值取0.15 ng/(ml·cm^3)时,其对PCa诊断敏感性为86.23%,特异性为57.84%。结论 f/tPSA和PSAD对鉴别PCa与BPH伴前列腺炎具有重要意义,PSAD对PCa诊断的敏感性、特异性均高于f/tPSA。 Objective To investigate the efficacy of PSA, f/tPSA and PSAD in the diagnosis of prostatic cancer(PCa) and benign prostatic hyperplasia(BPH) accompanied prostatitis. Methods A retrospective analysis was made of 96 patients with prostate diseases whose tPSA was located in 4-10 ng/ml from September 2016 to September 2018. Pathologically confirmed 26 patients was PCa and 70 patients was BPH complicated with prostatitis. tPSA, free PSA(fPSA), PSA ratio(f/tPSA), PSA density(PSAD) were counted. The sensitivity and specificity of f/tPSA and PSAD were calculated respectively. Results There was no significant difference between two groups in tPSA(P>0.05). The serum f/tPSA in PCa group was significantly lower than that in BPH with prostatitis group(P<0.05), and the PSAD in PCa group was significantly higher than that in BPH group(P<0.05). When the critical value of f/tPSA was 0.16, the diagnostic sensitivity was 70.11% and the specificity was 57.10%. When the critical value of PSAD was 0.15 ng/ml/cm^3, the diagnostic sensitivity was 86.23% and the specificity was 57.84%. Conclusions PSAD is more suitable for differentiating BPH and PCa than f/tPSA.
作者 孙珂 高佃军 Sun Ke;Gao Dianjun(Affiliated Hospital of Weifang Medical College,Weifang 261031,China)
出处 《临床医学》 CAS 2019年第4期15-17,共3页 Clinical Medicine
关键词 前列腺癌 前列腺增生伴前列腺炎 前列腺特异性抗原比值 前列腺特异性抗原密度 Prostatic cancer Benign prostatic hyperplasia accompanied prostatitis Prostate specific antigen ratio Prostate specific antigen density
  • 相关文献

参考文献7

二级参考文献55

  • 1胡少龙,许健波,马拥军.前列腺特异抗原在前列腺癌诊断中的价值探讨[J].中华检验医学杂志,1998,22(3):19-21. 被引量:20
  • 2蒋显勇,刘庆武,刘忠元,罗红英.血清tPSA、f/t比值及PSAD在鉴别前列腺良恶性病变中的价值[J].现代检验医学杂志,2005,20(5):4-6. 被引量:6
  • 3魏丽琴,孙文伟,马庆杰,李扬.DELFIA检测血清PSA、fPSA及fPSA/PSA在前列腺疾病诊断中的应用[J].吉林大学学报(医学版),2006,32(5):851-853. 被引量:5
  • 4赵琛,赵辉,高勇.良性前列腺增生症血清PSA检测的临床意义[J].吉林大学学报(医学版),2007,33(2):372-372. 被引量:4
  • 5王寅 黄长海 等.前列腺特异抗原不同评价结果与前列腺癌的关系分析[J].中华医学杂志,2000,80(9):678-680.
  • 6Nadler RB, Loeb S, Kimberly AR, et al. Use of 2. 6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol, 2005, 174, 2154-2157.
  • 7Gilbert SM, Christina BC, Kahane H, et al. Evedence suggesting PSA cutpoint of 2.5 ng/ml, for prompting prostate biopsy: review of 36,316 biopsies. Urol, 2005, 65: 549-553.
  • 8Kobayashi T, Nishizawa K, Ogura K ,et al. Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/ml, equivalent to that in men witn 4. 1 to 10.0 ng/ml, in a Japanese population. Urol, 2004, 63: 727-731.
  • 9Scott EE, Kimberly AR, William JC. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml, and an initially negative biopsy. J Urol, 2005, 174: 500-504.
  • 10Gilbert H, Welch LM. Schwartz and Steven Woloshin. Prostatespecific antigen levels in the united states: Implications of various definitions for abnormal. J National Cancer Institute, 2005, 97: 1132-1137.

共引文献116

同被引文献103

引证文献10

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部